Skip to main content

Meet with our product experts in one-on-one virtual sessions

Set Up a Meeting
Quick Connect

White Paper

Product Alert – Mavacamten API

Product Alert – Mavacamten API

CAS no. 1642288-47-8

Mavacamten (Camzyos®) is the pioneering and singularly authorised cardiac myosin inhibitor designed to address hypertrophic cardiomyopathy (HCM) at its root cause. This unique compound acts as an allosteric and reversible inhibitor with a specific focus on cardiac myosin, allowing for the controlled adjustment of the myosin heads' activity, thus decreasing the formation of myosin-actin cross-bridges.

Dr. Reddy's API Offering

  • We are developing Innovator Crystalline Form A - Labs samples; COA is available.
  • Alternate polymorph/ novel form will provide 4 to 6 years of advantage.

Our cGMP API manufacturing facility has undergone a thorough inspection by international regulatory authorities, and we have reliable suppliers for key starting materials to ensure timely deliveries and adherence to strict specifications. Moreover, we are equipped to provide sufficient capacity to supply development quantities within a short lead time of 90-120 days.

To learn more about our API offerings, please read the product alert on Mavacamten API by filling out the contact form below.

Explore other Whitepapers:

Know More

Download Now

Please fill the Contact form below in order to view the white paper


No information in this catalog - including any reference to any product or service - constitutes an offer for sale, or be construed as representing an offer for sale. Products protected under valid patents are not offered or supplied for commercial use. However, the research quantities of such products may be offered for the purpose of regulatory submissions, wherever such regulatory exemptions exist. The buyers should make their independent evaluation of the patent scenario for their respective markets and will be responsible for all patent related liabilities. Products protected under valid patents in India are not available for commercial use but would be available for Section 107A purposes.